CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging, announced today that it has signed an exclusive license agreement with the Massachusetts Institute of Technology for intellectual property related to SIRT1 as a novel mechanism that affects atherosclerosis and other age-related diseases. Specifically, this agreement provides Sirtris with exclusive rights to intellectual property covered under the patent "Cholesterol-Regulating Complex of SIRT1 and LXR and Methods of Use."
